Shares of Stemline Therapeutics Inc. (NASDAQ:STML) have been assigned an average recommendation of “Buy” from the six research firms that are presently covering the company. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $23.50.

A number of equities research analysts have issued reports on the company. Zacks Investment Research cut Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 11th. Wedbush restated an “outperform” rating and set a $15.00 price objective on shares of Stemline Therapeutics in a research note on Tuesday, November 8th. Roth Capital restated a “buy” rating and set a $32.00 price objective on shares of Stemline Therapeutics in a research note on Friday, November 11th. Finally, Jefferies Group restated a “buy” rating on shares of Stemline Therapeutics in a research note on Friday, August 5th.

Stemline Therapeutics (NASDAQ:STML) opened at 12.20 on Tuesday. The firm has a 50-day moving average of $11.85 and a 200-day moving average of $8.66. The stock’s market capitalization is $217.72 million. Stemline Therapeutics has a 12-month low of $3.88 and a 12-month high of $14.20.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Baker BROS. Advisors LP purchased a new position in Stemline Therapeutics during the third quarter worth about $3,612,000. Candriam Luxembourg S.C.A. purchased a new position in Stemline Therapeutics during the third quarter worth about $2,783,000. Franklin Resources Inc. raised its position in Stemline Therapeutics by 11.8% in the second quarter. Franklin Resources Inc. now owns 2,102,200 shares of the biopharmaceutical company’s stock worth $14,232,000 after buying an additional 222,170 shares during the last quarter. Columbus Circle Investors purchased a new position in Stemline Therapeutics during the third quarter worth about $1,577,000. Finally, BlackRock Institutional Trust Company N.A. raised its position in Stemline Therapeutics by 27.6% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 239,232 shares of the biopharmaceutical company’s stock worth $2,591,000 after buying an additional 51,804 shares during the last quarter. 53.21% of the stock is currently owned by hedge funds and other institutional investors.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

5 Day Chart for NASDAQ:STML

Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.